Rufinamide

Drugbox
IUPAC_name = 1- [(2,6-difluorophenyl)methyl] triazole-4-carboxamide

---

CAS_number=106308-44-5
ATC_prefix=N03
ATC_suffix=AF03
ATC_supplemental=
PubChem=129228
DrugBank=
C=10 | H=8 | F=2 | N=4 | O=1
molecular_weight = 238.194
bioavailability=
metabolism =
elimination_half-life=
excretion =
pregnancy_category =
legal_status =
routes_of_administration= "Rufinamide" is an anticonvulsant medication.

It has been used in combination with other medication and therapy to treat Lennox-Gastaut syndromecite journal |author=Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW |title=Rufinamide: a new anti-epileptic medication |journal=Expert Opin Pharmacother |volume=8 |issue=12 |pages=1931–40 |year=2007 |month=August |pmid=17696794 |doi=10.1517/14656566.8.12.1931 |url=http://www.expertopin.com/doi/abs/10.1517/14656566.8.12.1931] and various other seizure disorders, Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.

It is not currently approved in the United States.cite journal |author=Chung AM, Eiland LS |title=Use of second-generation antiepileptic drugs in the pediatric population |journal=Paediatr Drugs |volume=10 |issue=4 |pages=217–54 |year=2008 |pmid=18590343 |doi= |url=]

References

* [http://www.drugs.com/nda/rufinamide_050913.html Drugs.com - Rufinamide]
* [http://www.epilepsy.com/epilepsy/medicine_rufinamide.html Epilepsy.com - Rufinamide]